The telehealth-consultation platform said it plans to continue expanding its weight loss offerings.

HIMS has experienced similar dramatic drops before. During the 2022 inflation surge, the stock fell 87%, and in 2020, it ...

Telehealth firm Hims & Hers Health said on Tuesday it plans to sell Eli Lilly's weight-loss drug, as it widens its offerings ...

Hims & Hers Health (NYSE:HIMS) stock gains as the company adds Eli Lilly's (LLY) weight loss therapy tirzepatide & generic liraglutide to its platform. Read more here.

Hims & Hers Health Inc.’s shares jumped Tuesday after it said it was broadening its weight-loss offerings, adding access to brand name shots like Zepbound after previously focusing on cheaper versions ...

Detailed price information for Hims & Hers Health Inc (HIMS-N) from The Globe and Mail including charting and trades.

The telehealth company Hims & Hers is adding Zepbound and generic liraglutide to its offering of weight-loss drugs.

CNBC's Brandon Gomez joins 'Closing Bell' to discuss Hims & Hers shares rising as company adds new weight-loss medications to platform.

Hims & Hers Health shares jumped Tuesday as the company added Eli Lilly’s weight-loss drug Zepbound and diabetes treatment Mounjaro to its telehealth platform.

Eli Lilly quickly disassociated itself from Hims & Hers after the telehealth company said it was selling the pharmaceutical company’s weight-loss drug.

Hims & Hers Health HIMS-6.01%decrease ... loss offerings with the addition of Eli Lilly LLY 0.35%increase; green up pointing triangle & Co. Zepbound and generic liraglutide.